Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)

EPA:ALOPM Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 22, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Market Capitalization	7	7	13	30	12
Market Cap Growth	15.62%	-42.44%	-56.74%	155.14%	-
Enterprise Value	11	12	11	23	-
Last Close Price	0.34	0.41	0.71	1.81	1.70
PE Ratio	1.14	1.36	-	-	-
Forward PE	-	0.21	-	-	-
PS Ratio	3.59	4.12	7.93	17.24	1.42
PB Ratio	1.12	1.29	-30.21	8.13	1.00
P/TBV Ratio	1.37	1.57	-	11.79	1.07
EV/Sales Ratio	5.95	6.37	7.01	13.18	-
EV/EBITDA Ratio	1.78	1.91	-	-	-
EV/EBIT Ratio	1.89	2.02	-	-	-
Debt / Equity Ratio	1.10	1.10	-17.65	2.39	0.22
Debt / EBITDA Ratio	1.06	1.06	-	-	-
Net Debt / Equity Ratio	0.74	0.74	-5.37	-0.41	-0.91
Net Debt / EBITDA Ratio	0.71	0.71	-0.31	0.16	7.45
Asset Turnover	0.14	0.14	0.12	0.10	-
Quick Ratio	0.38	0.38	2.65	3.45	4.10
Current Ratio	1.86	1.86	2.80	3.53	4.14
Return on Equity (ROE)	203.90%	203.90%	-442.13%	-104.58%	-
Return on Assets (ROA)	27.76%	27.76%	-35.69%	-35.51%	-
Return on Invested Capital (ROIC)	56.32%	94.93%	-384.64%	-623.13%	-159.34%
Return on Capital Employed (ROCE)	72.60%	72.60%	-102.40%	-79.20%	-11.20%
Earnings Yield	84.15%	73.39%	-55.58%	-26.98%	-1.97%
Buyback Yield / Dilution	-1.34%	-1.34%	-9.16%	0.48%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 22, 2026

Data Sources Report a data error